Ian Cawich, MD
Basic profileIan Cawich is a Cardiology physician affiliated with Arkansas Heart Hospital. OpenAlex indexes 35 publications with 902 citations (h-index 12).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingIndustry payments
34 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Shockwave Medical, IncProgram year202547 payments$28,649
- AbbottProgram year20256 paymentsResearch$3,734
- Abbott LaboratoriesProgram year202517 payments$1,377
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
57.5%Beta blocker11.5%Metoprolol Succinate54%Metoprolol Tartrate23%Carvedilol11%Atenolol6%Sotalol4%Bisoprolol Fumarate3%Part D<11 patientsStatin8.6%Atorvastatin Calcium53%Rosuvastatin Calcium20%Pravastatin Sodium12%Simvastatin11%Lovastatin5%Part D<11 patients+ 16 more classes in this area
Blood & clotting
36%P2Y12 inhibitor24.6%Clopidogrel90%Prasugrel Hcl7%Brilinta3%Part D<11 patientsFactor Xa inhibitor9.6%Eliquis82%Xarelto18%Part D≥73 patients+ 2 more classes in this area
Metabolism & gastrointestinal
4.2%Potassium supplement2.3%Potassium Chloride100%Part D≥30 patientsProton pump inhibitor1.6%Omeprazole68%Pantoprazole Sodium32%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- From Coronary Arteries to Lower Limbs: Advances in Drug-Eluting Bioresorbable Scaffolds for Treating Chronic Limb-Threatening Ischemia
Journal of Endovascular Therapy
2025 - Temsirolimus Adventitial Delivery to Improve ANGiographic Outcomes below the Knee (TANGO)
Zenodo (CERN European Organization for Nuclear Research)
2024 - Temsirolimus Adventitial Delivery to Improve ANGiographic Outcomes Below the Knee
Journal of Endovascular Therapy
2022 - DIAMondback Atherectomy With OCT Visualization for Calcified PAD Lesions (DIAMOCT-PAD Study)
The Journal of invasive cardiology/The journal of invasive cardiology
2022 - Multivessel Versus Culprit-Vessel Percutaneous Coronary Intervention in Cardiogenic Shock
JACC: Cardiovascular Interventions
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Scott Beau, MD
Arkansas Heart Hospital
David Mego, MD
Arkansas Heart Hospital
Andre Paixao, MD
Arkansas Heart Hospital
Andrew Hinson, MD
Arkansas Heart Hospital
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Martin Leon, MD
Columbia University Irving Medical Center
Gregg Fonarow, MD
Ronald Reagan UCLA Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”